Migraine is the 3rd most prevalent illness and one of the most common neurological diseases in the world. It is estimated that around 1.04 billion people worldwide have been diagnosed with migraines. One of the symptoms of migraine is a one-sided pulsating headache with average to a severe intensity which is aggravated by physical activity. It is often accompanied by an aversion to light and sound and with nausea or vomiting, lasting from 4 to 72 hours. About 20 million migraine attack occurs every day. Three times more adult women suffer from migraine than adult men. About 10% of the children between ages 5-15 suffer from the disease. About 50% of women with migraine have more than one attack during a month. In addition to disability, migraine increases the risk of other mental and physical problems. It imposes huge financial and psychological costs on families, companies, and countries. The average health costs of a family with a migraine patient are 70% more than those of a family without such a member.
Pre-clinical research and development of Migraine Spray comprise them in research efforts implemented towards developing a novel herbal drug for migraine headaches. The research started in 2008. With the emergence of promising preliminary results from the ingredients, research focused on developing a drug has been followed.
In the beginning, the drug was in the shape of powder and was to be processed and inhaled by the migraine patients in special apparatus in clinics. It was expensive and not available to most patients. After many years of rigorous research to make the drug easy-to-use and available to all, the R&D team of MIM Pharma developed a new version of migraine medicine. In 2019, Migraine Spray passed all the requirements and clinical trials that were performed based on the International Headache Society (IHS) guidelines on 2000 patients. Based on our extensive clinical trial, the drug performs as a very strong anti-migraine with remarkable curative migraine effects!
Mechanism Of Action
Migraine patients with episodic and chronic headaches have shown a significant decrease in their severity and clinical symptoms indices after using Migraine Spray. The patients suffering from “medication overuse headache” (MOH) also benefitted from Migraine Spray, but usually throughout a longer period of time with similar or even better results of treatment. Patients with migraine accompanied by cluqer and tension headaches also had their migraines decreased by using Migraine Spray. But the reduction of other types of headaches requires special treatments and counselling by neurologists. Migraine Spray has proven effective in curing and reduction of various kinds of migraines in different people for different reasons. In fact, the change in the diameter of the blood vessels in the head (the brain) for managing headaches, enhancing melatonin secretion to improve sleep quality, and biological rhythms and decreasing the free nitric acid in the blood are among the powerful action mechanisms of the medicine.
Dosage and Usage
The highest amount of Migraine Spray that is used for curative treatment course is one puff in each nostril every three hours from 9 a.m. to 12 a.m. The minimum daily amount is three puffs in each nostril. The intervals, including 4, 6, or 8 hours between the two puffs, are determined by the counsellors or specialists, according to the state of the headaches or the clinical conditions of the patients.
In addition, Migraine Spay is also taken during a migraine attack. Such usage should not interfere with the regular treatment time-table, e.g., if the Migraine Spray is to be taken at 3 p.m. based on the prescription time-table and an attack occurs at 2 p.m. and the medicine is taken on the preventive basis, then the patient has to take the medicine at 3 p.m. too to comply with the regular time-table.
If the Migraine Spray is taken based on the instructions in the medicine brochure, each bottle of the spray lasts for about 10 days. This duration can be extended to 25 days in case other permitted timings are applied.
The desired migraine treatment duration, as concluded from the clinical trials, has been about four months, meaning that at least six bottles of spray are recommended to the patients.
Using Migraine Spray while taking anticoagulants or trinitroglycerin is not recommended. In addition, children under the age of 12 and pregnant women are prohibited from using the medicine.